Wall Street brokerages expect Retrophin, Inc. (NASDAQ:RTRX) to report sales of $40.82 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Retrophin’s earnings, with the lowest sales estimate coming in at $39.14 million and the highest estimate coming in at $42.50 million. Retrophin posted sales of $33.95 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 20.2%. The firm is expected to issue its next earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that Retrophin will report full-year sales of $40.82 million for the current fiscal year, with estimates ranging from $152.69 million to $154.80 million. For the next year, analysts forecast that the business will post sales of $184.40 million per share, with estimates ranging from $184.19 million to $184.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Retrophin.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.10). Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The business had revenue of $38.80 million during the quarter, compared to analysts’ expectations of $37.36 million. During the same quarter in the prior year, the firm earned $0.07 EPS. The firm’s revenue for the quarter was up 16.5% compared to the same quarter last year.

RTRX has been the subject of a number of recent analyst reports. ValuEngine raised Retrophin from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. BidaskClub raised Retrophin from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 24th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $44.00 price objective on shares of Retrophin in a research report on Friday. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Retrophin has an average rating of “Buy” and an average price target of $36.00.

Retrophin (NASDAQ:RTRX) opened at 24.72 on Monday. The stock has a 50 day moving average price of $23.99 and a 200 day moving average price of $20.09. Retrophin has a 1-year low of $15.55 and a 1-year high of $25.44. The stock’s market cap is $948.88 million.

In other Retrophin news, COO Neil F. Mcfarlane sold 1,378 shares of Retrophin stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total transaction of $31,005.00. Following the completion of the sale, the chief operating officer now owns 13,622 shares of the company’s stock, valued at approximately $306,495. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 2.41% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC lifted its position in Retrophin by 4.5% during the 1st quarter. Perceptive Advisors LLC now owns 2,807,525 shares of the biopharmaceutical company’s stock worth $51,826,000 after acquiring an additional 120,113 shares during the period. FMR LLC lifted its position in Retrophin by 24.8% during the 1st quarter. FMR LLC now owns 1,958,875 shares of the biopharmaceutical company’s stock worth $36,161,000 after acquiring an additional 389,714 shares during the period. Vanguard Group Inc. lifted its position in Retrophin by 8.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,635,234 shares of the biopharmaceutical company’s stock worth $31,707,000 after acquiring an additional 125,695 shares during the period. Macquarie Group Ltd. lifted its position in Retrophin by 17.0% during the 2nd quarter. Macquarie Group Ltd. now owns 1,188,819 shares of the biopharmaceutical company’s stock worth $23,051,000 after acquiring an additional 172,389 shares during the period. Finally, Oak Ridge Investments LLC lifted its position in Retrophin by 96.9% during the 2nd quarter. Oak Ridge Investments LLC now owns 1,022,871 shares of the biopharmaceutical company’s stock worth $19,833,000 after acquiring an additional 503,428 shares during the period.

WARNING: “$40.82 Million in Sales Expected for Retrophin, Inc. (RTRX) This Quarter” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/09/40-82-million-in-sales-expected-for-retrophin-inc-rtrx-this-quarter-2.html.

Retrophin Company Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Get a free copy of the Zacks research report on Retrophin (RTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.